EC To Impose Constraints On Sandoz/Ciba-Geigy Merger

30 June 1996

- The European Commission in Brussels is expected to impose regulations on the Sandoz and Ciba-Geigy merger as a result of their prominent places in the market of crop-protection products. Once EC conclusions have been reached, possibly at the end of July, it is expected that the merged company, Novartis, will have to sell off certain business units in this sector in order to improve competition. The company would otherwise monopolize 50% of the market, worth an estimated $6.06 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight